胸腹联合食管切除术:过去与现在
基于全球食管癌协作组数据库8854例食管切除术患者,采用倾向性评分匹配比较胸腹联合食管切除术(TAE)与非TAE的生存,并报告本中心2017至2021年TAE的应用现状与结局。全球TAE组5年生存34%低于非TAE组42%;高容量中心TAE的3年生存与全球非TAE相当。
要点
- 全球匹配队列中,TAE组中位淋巴结清扫20枚多于非TAE组17枚(P < .0001)。
- 全球TAE组5年生存34%,低于全球非TAE组的42%(P = .04)。
- 高容量中心TAE组3年生存52%,与全球非TAE组54%相比无显著差异(P = .1)。
核心结论
- 当TAE作为高容量中心的主要术式时,其结局可与非TAE相当且并发症发生率低。
- 目前作者认为TAE最适用于躯干肥胖、既往腹部手术史及局部进展期贲门肿瘤且切除范围可能不定的患者。
研究设计与样本
- 全球食管癌协作组数据库纳入2005至2014年间8854例因癌症行食管切除术的患者,该期间TAE为本中心最常用术式。
- 构建两个倾向性评分匹配模型:全球TAE对比全球非TAE(751对匹配),以及本高容量中心TAE对比全球非TAE(273对匹配)。
- 比较匹配组间的全因死亡率,并评估本中心2017至2021年TAE的现时应用与结局。
主要发现
- 全球倾向性评分匹配后,TAE组中位淋巴结清扫数为20枚,非TAE组为17枚(P < .0001)。
- 全球TAE组5年生存率为34%,全球非TAE组为42%(P = .04)。
- 高容量中心TAE组3年匹配生存率为52%,全球非TAE组为54%(P = .1)。
- 2017至2021年本中心346例食管切除术中90例(26%)采用TAE。
- 本中心TAE后5例(5.6%)发生肺炎,88例(98%)在30天时存活,与胸外科医师学会同期平均水平相当。
临床怎么用
- 作者认为,TAE在高容量中心作为主要术式时结局可与非TAE相当且并发症发生率低。
- 作者认为,目前TAE最适用于躯干肥胖、既往腹部手术史及局部进展期贲门肿瘤且切除范围可能不定的患者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Open approaches for esophagectomy are often still useful; of these, left thoracoabdominal esophagectomy (TAE) is poorly understood and often criticized. Hence, we examined TAE's worldwide utilization, survival, and present-day use and outcomes at our institution compared with contemporary national averages. METHODS: The Worldwide Esophageal Cancer Collaboration database includes 8854 patients who underwent esophagectomy for cancer between 2005 and 2014, a period when TAE was our center's most common approach. Two propensity score-matched models were constructed: worldwide TAE vs worldwide non-TAE (751 matched pairs); and our high-volume center TAE vs worldwide non-TAE (273 matched pairs). All-cause mortality was compared between matched groups. Institutional TAE data from 2017 to 2021 were assessed for present-day use and outcomes. RESULTS: Worldwide, propensity score-matched patients undergoing TAE had a median of 20 lymph nodes resected vs 17 after non-TAE (P < .0001). Five-year survival was 34% for worldwide TAE vs 42% for worldwide non-TAE groups (P = .04). Three-year matched survival was 52% for high-volume TAE compared with 54% for worldwide non-TAE groups (P = .1). From 2017 to 2021 at our institution, 90 (26%) of 346 esophagectomies were performed by TAE. Pneumonia developed in 5 patients (5.6%), with 88 patients (98%) alive at 30 days, comparable to contemporary averages of The Society of Thoracic Surgeons. CONCLUSIONS: When it is performed as the primary approach in high volumes, TAE can have comparable outcomes to non-TAE with low morbidity. At present, we find that TAE is most useful in patients with truncal obesity, prior abdominal operations, and locally advanced cardia tumors with potential for variable extent of resection.
引用
- Barron JO, Blackstone EH, Rice TW, et al. Thoracoabdominal Esophagectomy: Then and Now. Ann Thorac Surg. 2024. PMID: 38290595. doi:10.1016/j.athoracsur.2023.12.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。